| ID Source | ID |
|---|---|
| PubMed CID | 1075698 |
| CHEMBL ID | 1321933 |
| CHEBI ID | 93518 |
| Synonym |
|---|
| STK609594 |
| 1-(3,4-dichlorophenyl)-3-[(2z)-5-(pyridin-4-yl)-1,3,4-thiadiazol-2(3h)-ylidene]urea |
| AKOS005544805 |
| MLS000559245-02 |
| NCGC00187635-02 |
| NCGC00187635-01 |
| MLS000559245 , |
| smr000178207 |
| 1-(3,4-dichloro-phenyl)-3-(5-pyridin-4-yl-[1,3,4]thiadiazol-2-yl)-urea |
| BAS 04852923 |
| STK061520 |
| 1-(3,4-dichlorophenyl)-3-[5-(pyridin-4-yl)-1,3,4-thiadiazol-2-yl]urea |
| AKOS000599794 |
| 1-(3,4-dichlorophenyl)-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea |
| HMS2522B18 |
| MLS003370592 |
| CHEMBL1321933 |
| cid_1075698 |
| 1-(3,4-dichlorophenyl)-3-[5-(4-pyridyl)-1,3,4-thiadiazol-2-yl]urea |
| bdbm48721 |
| CHEBI:93518 |
| Q27165214 |
| Z2734691022 |
| Class | Description |
|---|---|
| ureas | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 4.3503 | 0.0040 | 23.8416 | 100.0000 | AID485290; AID489007 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 10.0000 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 2.5119 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| WRN | Homo sapiens (human) | Potency | 2.6887 | 0.1683 | 31.2583 | 100.0000 | AID651768; AID720497 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 3.2643 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 3.4635 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 1.0000 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 3.1623 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| Parkin | Homo sapiens (human) | Potency | 4.0234 | 0.8199 | 14.8306 | 44.6684 | AID720549; AID720555 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 5.0119 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 2.5483 | 0.5406 | 17.6392 | 96.1227 | AID2528; AID2585; AID720503 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 0.8913 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2242 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 6.3096 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 50.1187 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 7.0795 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 18.3749 | 0.0501 | 27.0736 | 89.1251 | AID588590; AID720496 |
| geminin | Homo sapiens (human) | Potency | 3.2643 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 1.7783 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 17.7828 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 0.8913 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 0.8913 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| calpain II, partial | Sus scrofa (pig) | IC50 (µMol) | 3.6356 | 1.7742 | 4.9338 | 7.7087 | AID1420 |
| Mcl-1 | Homo sapiens (human) | IC50 (µMol) | 9.8952 | 0.4000 | 7.1344 | 54.0000 | AID1417; AID1418 |
| DNA (cytosine-5)-methyltransferase 1 isoform b | Homo sapiens (human) | IC50 (µMol) | 1.2900 | 1.2900 | 8.7555 | 41.0000 | AID602386 |
| dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 (µMol) | 3.4300 | 0.4000 | 9.3610 | 90.0000 | AID1654; AID1878 |
| eukaryotic translation initiation factor 4 gamma 1 isoform 4 | Homo sapiens (human) | IC50 (µMol) | 64.0000 | 1.1500 | 12.6200 | 25.6529 | AID855 |
| eukaryotic translation initiation factor 4E isoform 1 | Mus musculus (house mouse) | IC50 (µMol) | 64.0000 | 1.1500 | 12.6200 | 25.6529 | AID855 |
| dual specificity protein phosphatase 6 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 16.2000 | 0.8320 | 24.1190 | 48.2000 | AID425 |
| Renin | Homo sapiens (human) | IC50 (µMol) | 5.3000 | 0.0000 | 0.7796 | 8.2000 | AID1654 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.0500 | 0.0005 | 2.7739 | 25.1700 | AID1418 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.0500 | 0.0005 | 2.8919 | 25.1700 | AID1418 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.0500 | 0.0005 | 2.7478 | 25.1700 | AID1418 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.0500 | 0.0005 | 2.7802 | 25.1700 | AID1418 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.0500 | 0.0005 | 3.3142 | 49.5000 | AID1418 |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 21.1000 | 0.0042 | 7.4680 | 21.1000 | AID2073 |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 21.1000 | 0.0003 | 7.3294 | 21.1000 | AID2073 |
| Bloom syndrome protein | Homo sapiens (human) | IC50 (µMol) | 1.4000 | 1.4000 | 2.0875 | 3.0000 | AID771544 |
| Werner syndrome ATP-dependent helicase | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 2.7000 | 3.7000 | 5.0000 | AID771543 |
| BZLF2 | Human herpesvirus 4 type 2 (Epstein-Barr virus type 2) | IC50 (µMol) | 2.5400 | 0.4200 | 4.4342 | 16.2300 | AID1419 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID771541 | Selectivity ratio of IC50 for WRN (unknown origin) to IC50 for BLM (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20 | Synthesis and SAR studies of 5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine derivatives as potent inhibitors of Bloom helicase. |
| AID771543 | Inhibition of WRN (unknown origin) by gel-based DNA unwinding assay | 2013 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20 | Synthesis and SAR studies of 5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine derivatives as potent inhibitors of Bloom helicase. |
| AID771542 | Inhibition of RECQ1 (unknown origin) by gel-based DNA unwinding assay | 2013 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20 | Synthesis and SAR studies of 5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine derivatives as potent inhibitors of Bloom helicase. |
| AID771544 | Inhibition of BLM (unknown origin) by gel-based DNA unwinding assay | 2013 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20 | Synthesis and SAR studies of 5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine derivatives as potent inhibitors of Bloom helicase. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID720549 | qHTS for Inhibitors of Bloom's syndrome helicase (BLM): Helicase ATPase Orthogonal Confirmatory Assay for SAR | 2013 | Chemistry & biology, Jan-24, Volume: 20, Issue:1 | A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.29) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||